clinical trial · NCT04196257
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Solid Tumor, AdultCarcinoma, Ovarian EpithelialFallopian Tube NeoplasmsEndometrial CancerPeritoneal CancerSolid TumorBP1001-A (Liposomal Grb2 Antisense Oligonucleotide)BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel
brief summary
This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety and the maximum tolerated dose (MTD) or maximum administered dose (MAD) of BP1001-A as a single agent. After the MTD or MAD of BP1001-A is established, the dose expansion phase will commence and determine the safety, toxicity and response of BP1001-A in combination with paclitaxel.
started
Aug 19, 2022
primary completion
Jul 1, 2027
completion
Oct 1, 2027
last updated
Mar 7, 2025
official title
A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients With Advanced or Recurrent Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol